355 related articles for article (PubMed ID: 20655243)
1. Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals.
Barthélémy P; Heitz D; Mathelin C; Polesi H; Asmane I; Litique V; Rob L; Bergerat JP; Kurtz JE
Crit Rev Oncol Hematol; 2011 Aug; 79(2):196-204. PubMed ID: 20655243
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy in elderly patients with colorectal cancer. A retrospective analysis of the implementation of tumor board recommendations in a single institution.
Kurtz JE; Heitz D; Serra S; Brigand C; Juif V; Podelski V; Meyer P; Litique V; Bergerat JP; Rohr S; Dufour P
Crit Rev Oncol Hematol; 2010 Jun; 74(3):211-7. PubMed ID: 19560368
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
4. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients.
DeMichele A; Putt M; Zhang Y; Glick JH; Norman S
Cancer; 2003 May; 97(9):2150-9. PubMed ID: 12712466
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer in elderly women: outcome as affected by age, tumor features, comorbidities, and treatment approach.
Siegelmann-Danieli N; Khandelwal V; Wood GC; Mainali R; Prichard J; Murphy TJ; Evans JF; Yumen O; Bernath AM
Clin Breast Cancer; 2006 Apr; 7(1):59-66. PubMed ID: 16764745
[TBL] [Abstract][Full Text] [Related]
6. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
8. Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients.
Kuo SH; Lien HC; You SL; Lu YS; Lin CH; Chen TZ; Huang CS
Breast; 2008 Dec; 17(6):646-53. PubMed ID: 18595699
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients.
Bastiaannet E; Liefers GJ; de Craen AJ; Kuppen PJ; van de Water W; Portielje JE; van der Geest LG; Janssen-Heijnen ML; Dekkers OM; van de Velde CJ; Westendorp RG
Breast Cancer Res Treat; 2010 Dec; 124(3):801-7. PubMed ID: 20428937
[TBL] [Abstract][Full Text] [Related]
10. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
11. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
12. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer.
Lohrisch C; Paltiel C; Gelmon K; Speers C; Taylor S; Barnett J; Olivotto IA
J Clin Oncol; 2006 Oct; 24(30):4888-94. PubMed ID: 17015884
[TBL] [Abstract][Full Text] [Related]
13. Management of operable invasive breast cancer in women over the age of 70: long-term results of a large-scale single-institution experience.
Laki F; Kirova YM; Savignoni A; Campana F; Levu B; Estève M; Sigal-Zafrani B; Dorval T; Asselain B; Salmon RJ
Ann Surg Oncol; 2010 Jun; 17(6):1530-8. PubMed ID: 20177798
[TBL] [Abstract][Full Text] [Related]
14. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer treatment guidelines in older women.
Giordano SH; Hortobagyi GN; Kau SW; Theriault RL; Bondy ML
J Clin Oncol; 2005 Feb; 23(4):783-91. PubMed ID: 15681522
[TBL] [Abstract][Full Text] [Related]
16. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
[TBL] [Abstract][Full Text] [Related]
17. Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM).
Jara Sánchez C; Ruiz A; Martín M; Antón A; Munárriz B; Plazaola A; Schneider J; Martínez del Prado P; Alba E; Fernández-Aramburo A
Breast Cancer Res Treat; 2007 Jan; 101(2):215-23. PubMed ID: 16823507
[TBL] [Abstract][Full Text] [Related]
18. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
19. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
20. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands.
Sukel MP; van de Poll-Franse LV; Nieuwenhuijzen GA; Vreugdenhil G; Herings RM; Coebergh JW; Voogd AC
Eur J Cancer; 2008 Sep; 44(13):1846-54. PubMed ID: 18640030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
